340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
A few days have passed since the Justice Department informed former President Donald Trump that he had been indicted. Some of the main issues involved, both legal and political, are becoming clearer than they were in the first frenzied hours after the news broke.
First, the politics. The early indications are that predictions that Trump supporters would rally around him in the event of an indictment appear to be true. A poll by CBS News and YouGov found that 76% of likely Republican primary voters said that the indictment was politically motivated. When asked if the indictment would change their…
